@PaulMMCooper Much to my chagrin I totally missed this. Your producer is clearly a talent Paul! Just have the Han dynasty playing….once again. Can’t wait for the launch.
@PaulMMCooper@Fall_of_Civ_Pod still delivers the most immersive perspectives on human civilisations ever produced. We can always be tempted to learn more or find alternatives but this is still the tour de force of podcasts which one can listen to over and over again.
I'll be at the @YorkFestofIdeas this Sunday 2 June at 2pm talking about history, ruins, and the collapse of societies. If you're in York, come join me for a Q&A and book signing after! #Yorkideas https://t.co/AnF7WFtHEn
@Shackamaxon3day@Fall_of_Civ_Pod@PaulMMCooper While most of us, as young people, never appreciate how we became to be or how we developed as humans; ancient history trumps everything and @PaulMMCooper absolutely has reinvigorated my passion for history through his descriptive, immersive narrative. 10/10.
It’s technically a 5-0 present but incredibly excited to receive the book (signed!) based on the masterpiece @Fall_of_Civ_Pod which is authored by the amazing @PaulMMCooper…..incredibly grateful for all you do and the exquisite articulation of our history.
@DuthyTom@Fall_of_Civ_Pod@PaulMMCooper Dear Mr. Paul M. Cooper, Sir your ‘Documentary The fall of Civilizations ‘ is fantastic, informative, and wonderfully entertaining. This should be required viewing for all ages . Thank You for your wonderful talents. You Sir are blessed.
After listening so often to the @PaulMMCooper@Fall_of_Civ_Pod on the incredible Assyrian Empire it was an immersive experience to live and breathe King Ashurbanipal’s Lion Hunt Reliefs at the @britishmuseum along with all the amazing Assyrian relics. Thank you Paul !!!
Neurotech is conducting the world’s first human clinical study to treat children with Rett syndrome.
NTIRTT1 is a single-arm, open-label, Phase I/II clinical trial that will recruit 14 paediatric patients with a clinical diagnosis of Rett syndrome.
Highlights include:
“Off-the-shelf” capabilities of our CAR-#iNKT platform;
Potential benefits of CAR-iNKT cells over CAR-T in treating cancers;
The potential of $ALA-101 in combination with Imugene’s onCARlytics platform to treat solid tumours.
|> https://t.co/RAq6VqMOwu
$ALA Arovella Therapeutics presents iNKT cell platform at leading allogenic cell therapy summit in Boston https://t.co/bSkFr8X5JJ @WeAreArovella#ALA#ASX#ASXNews